If a pharmaceutical company develops a drug selectively inhibiting phosphodiesterase type 6 (PDE6) in retinal photoreceptor cells, which consequence follows for a patient taking this drug?

💡 Explanation

PDE6 hydrolyzes cGMP, which is crucial for closing cation channels in photoreceptors; cones require rapid phototransduction. Inhibiting PDE6 elevates cGMP, desensitizing cones, because continuous depolarization overwhelms the cell's dynamic range; therefore, the result is impaired phototransduction in cone cells rather than enhanced rod function or improved adaptation.

• Why does a patient with longstanding type 2 diabetes often require increasing insulin dosages to manage blood glucose levels, despite initially responding to lower doses?
• Why does pulmonary edema worsen when lymphatic drainage is blocked, causing increased interstitial fluid and alveolar flooding?
• Why does the nucleus accumbens exhibit increased activity during initial drug use, but decreased sensitivity over chronic addiction?
• If retinal ganglion cells in the eye experience prolonged glutamate excitotoxicity, which consequence follows for visual perception?
• If a marathon runner only consumes electrolyte-free water during a race, which consequence follows regarding plasma osmolality and ADH secretion?
• If a patient experiences chronic pain despite typical analgesic treatment, which mechanism involving nociceptor signal transduction is most likely contributing to this resistance?